(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid en es it fr

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Brand names, (5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Analogs

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Brand Names Mixture

  • No information avaliable

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Chemical_Formula

C20H30O2

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid RX_link

No information avaliable

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid fda sheet

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid msds (material safety sheet)

http://www.emdbiosciences.com/msds/English/324875English.pdf

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Synthesis Reference

No information avaliable

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Molecular Weight

302.456 g/mol

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Melting Point

No information avaliable

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid H2O Solubility

No information avaliable

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid State

Oily Liquid

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid LogP

6.23 +/- 0.48

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Dosage Forms

Capsule (usually in fish oil in a combination with DHA)

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Indication

EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Pharmacology

Eicosanoids are chemical messengers derived from 20-carbon polyunsaturated fatty acids that play critical roles in immune and inflammatory responses. Both 20-carbon omega-6 fatty acids (arachidonic acid) and 20-carbon omega-3 fatty acids (EPA) can be found in cell membranes. During an inflammatory response, arachidonic acid and EPA are metabolized by enzymes known as cyclooxygenases and lipoxygenases to form eicosanoids. Increasing omega-3 fatty acid intake increases the EPA content of cell membranes and decreases the arachidonic acid content, resulting in higher proportions of eicosanoids derived from EPA. Physiologic responses to arachidonic acid-derived eicosanoids differ from responses to EPA-derived eicosanoids. In general, eicosanoids derived from EPA are less potent inducers of inflammation, blood vessel constriction, and clotting than eicosanoids derived from arachidonic acid.

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Absorption

No information avaliable

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid side effects and Toxicity

No information avaliable

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Patient Information

No information avaliable

(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Organisms Affected

No information avaliable